Literature DB >> 2510592

Antipseudomonal activity of simulated infusions of gentamicin alone or with piperacillin assessed by serum bactericidal rate and area under the killing curve.

J E Tisdale1, M T Pasko, J M Mylotte.   

Abstract

The objectives of this study were to (i) determine which of three simulated dosing regimens (gentamicin alone, simultaneous infusions of gentamicin and piperacillin, or staggered infusions of gentamicin and piperacillin) produced the fastest killing rate of Pseudomonas aeruginosa in serum, using the serum bactericidal rate (SBR) assay; and (ii) describe an alternative method of analysis of killing curves, the area under the killing curve (AUKC). Gentamicin alone or combined with piperacillin was added to heat-inactivated human serum to approximate drug concentrations achieved after the above-mentioned types of infusion. By a microdilution technique, seven strains of P. aeruginosa were exposed to no drug (control) and gentamicin alone or with piperacillin; colony counts were determined at hourly intervals for 5 h, and log10 CFU per milliliter was plotted versus time. Linear regression was used to calculate the slope (SBR) of each timed killing curve for each drug concentration tested alone or in combination. In addition, the AUKC for each curve was calculated. To compare simulated infusion regimens further, the cumulative AUKC (the sum of AUKCs for specific time points along the serum concentration-time curve for each simulated regimen) was calculated. With the SBR assay or AUKC determination, there was a significant increase in the rate of killing of all test strains by the combination compared with gentamicin alone only at gentamicin concentrations which exceeded the MIC (8, 5, and 2.5 micrograms/ml). Mean cumulative AUKC of the simultaneous-infusion regimen was significantly less (indicating faster killing) than either the staggered-infusion regimen or the gentamicin infusion alone. Both the SBR and AUKC have the potential for integration of in vitro microbiologic effects and in vivo pharmacokinetics of antimicrobial agents.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2510592      PMCID: PMC172690          DOI: 10.1128/AAC.33.9.1500

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  An artificial capillary in vitro kinetic model of antibiotic bactericidal activity.

Authors:  S H Zinner; M Husson; J Klastersky
Journal:  J Infect Dis       Date:  1981-12       Impact factor: 5.226

Review 2.  Antibiotic synergism and antimicrobial combinations in clinical infections.

Authors:  G M Eliopoulos; R C Moellering
Journal:  Rev Infect Dis       Date:  1982 Mar-Apr

3.  A method for testing for synergy with any number of agents.

Authors:  M C Berenbaum
Journal:  J Infect Dis       Date:  1978-02       Impact factor: 5.226

4.  New in vitro kinetic model for evaluating bactericidal efficacy of antibiotics.

Authors:  T Murakawa; H Sakamoto; T Hirose; M Nishida
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

5.  Sodium polyanethol sulfonate inactivation of aminoglycosides.

Authors:  D J Krogstad; P R Murray; G G Granich; A C Niles; J H Ladenson; J E Davis
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

6.  Piperacillin kinetics.

Authors:  V K Batra; J A Morrison; K C Lasseter; V A Joy
Journal:  Clin Pharmacol Ther       Date:  1979-07       Impact factor: 6.875

7.  Aminoglycoside-selected subpopulations of Pseudomonas aeruginosa: characterization and virulence in normal and leukopenic mice.

Authors:  A U Gerber; W A Craig
Journal:  J Lab Clin Med       Date:  1982-11

8.  Selection of aminoglycoside-resistant variants of Pseudomonas aeruginosa in an in vivo model.

Authors:  A U Gerber; A P Vastola; J Brandel; W A Craig
Journal:  J Infect Dis       Date:  1982-11       Impact factor: 5.226

9.  Enhancing effect of serum ultrafiltrate on the activity of cephalosporins against gram-negative bacilli.

Authors:  J E Leggett; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

Review 10.  The aminoglycosides.

Authors:  A M Ristuccia; B A Cunha
Journal:  Med Clin North Am       Date:  1982-01       Impact factor: 5.456

View more
  7 in total

1.  In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase.

Authors:  Dora E Wiskirchen; Pornpan Koomanachai; Anthony M Nicasio; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

2.  Net effect of inoculum size on antimicrobial action of ampicillin-sulbactam: studies using an in vitro dynamic model.

Authors:  A A Firsov; M Ruble; D Gilbert; D Saverino; D Savarino; B Manzano; A A Medeiros; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

3.  Antimicrobial activity of human pancreatic juice and its interaction with antibiotics.

Authors:  E B Minelli; A Benini; C Bassi; H Abbas; M Falconi; F Locatelli; R de Marco; P Pederzoli
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

4.  Effect of polymorphonuclear neutrophils on serum bactericidal activity against Streptococcus pneumoniae after amoxicillin administration.

Authors:  M L Gómez-Lus; M J Giménez; J Prieto; M Martín; J Frías; L Aguilar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-01       Impact factor: 3.267

5.  Predictors of effect of ampicillin-sulbactam against TEM-1 beta-lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC.

Authors:  A A Firsov; D Saverino; D Savarino; M Ruble; D Gilbert; B Manzano; A A Medeiros; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

6.  Influence of pulmonary surfactant on in vitro bactericidal activities of amoxicillin, ceftazidime, and tobramycin.

Authors:  A van 't Veen; J W Mouton; D Gommers; J A Kluytmans; P Dekkers; B Lachmann
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

7.  Pharmacodynamics of Finafloxacin, Ciprofloxacin, and Levofloxacin in Serum and Urine against TEM- and SHV-Type Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections.

Authors:  A Dalhoff; S Schubert; A Vente
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.